ArticleHead & neck2025
Ultra-Hypofractionated Radiotherapy for Early-Stage Glottic Cancer: Real-World Data From a Single Center.
Article in Head & neck, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- MR-guided ultra-hypofractionated radiotherapy for early-stage glottic cancer: A phase I feasibility study.Clinical and translational radiation oncology · 2027Article
- Article
- Hypofractionated radiotherapy across cancer sites: a narrative review of evidence and implementation.Japanese journal of clinical oncology · 2026Review
- Definitive radiotherapy for early stage glottic cancer: a quarter-century of single-institution experience with long-term outcomes and late events.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Observational
- Global Disparities and Trends in Radiotherapy for Early-Stage Glottic Cancer.Current oncology (Toronto, Ont.) · 2026Article
- Ultra-Hypofractionated Radiotherapy for Early-Stage Glottic Cancer: Real-World Data From a Single Center.Head & neck · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn recent years, smaller-volume radiotherapy has attracted attention. It appears to be a safe and effective treatment for glottic laryngeal cancer. This study evaluated the results of ultra-hypofractionated radiotherapy for early glottic laryngeal cancer in unfit patients.
methodsThis retrospective study analyzed 22 patients diagnosed with early glottic cancer between June 2017 and January 2021. The involved vocal cord was treated with 35-42.5 Gy in 5 fractions.
resultsOn a 59-month median follow-up, the 5-year overall survival and local control rate were 68.2% and 94.7%, respectively. However, the 5-year larynx preservation rate was 89.7%. Chondronecrosis was observed in one patient (4.5%), and soft tissue necrosis in one patient (4.5%). PTV
conclusionSingle-cord ultra-hypofractionated radiotherapy appears to be an effective treatment for local control. However, the risk of radionecrosis is higher at doses above 41.08 Gy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.